IMVTIMVTHealthcare · Biotechnology

IMVT Stock Forecast: Immunovant, Inc. Price Predictions for 2026-2027

Last close, 17 Nov 2026
$33
−0.21% on the day

The 17 Wall Street analysts covering Immunovant, Inc. hold a median 12-month price target of $48 — +44.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 16 Nov 2026 — in the upper half.

Market cap
$6.9B
Ticker Nerd rank
58/ 100
Median analyst target
$48
Analysts covering
17
Revenue$0.0
Operating income−$160.3M
Net income−$153.2M
Free cash flow−$124.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.0%
1M
+24.2%
YTD
+30.6%
1Y
+36.7%
From 52W high
−26.1%
From 52W low
+50.8%
$22
$45
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IMVT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Immunovant, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 16 Nov 2026
58/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
85
Value
77
Volatility
73
Revisions
70
Growth
53
Accruals
48
Issuance
36
Quality
32
Size
19

Momentum (85): The shares have been drifting up relative to others.

Quality (32): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Size (19): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IMVT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMVT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26IMVTHigh $62Median $48Low $33

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
13 Buy4 Hold0 Sell
Low $33Median $48High $62

The green dot is the last close — the median target sits +44.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
10 Nov 2026Truist SecuritiesMaintainsHold$30 → $33
10 Nov 2026Wells FargoMaintainsOverweight$45 → $47
4 Aug 2026JP MorganMaintainsOverweight$47 → $50
4 Aug 2026JP MorganMaintainsOverweight—
30 June 2026CitigroupMaintainsBuy$57 → $61
30 June 2026CitigroupMaintainsBuy—
26 May 2026GuggenheimMaintainsBuy—
22 May 2026Truist SecuritiesMaintainsHold—
21 May 2026B of A SecuritiesMaintainsBuy—
21 May 2026HC Wainwright & Co.MaintainsBuy—
15 Apr 2026Goldman SachsMaintainsNeutral—
20 Mar 2026BernsteinInitiatesMarket Perform—
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
9 Feb 2026GuggenheimMaintainsBuy—
8 Jan 2026Truist SecuritiesMaintainsHold—
6 Jan 2026Wolfe ResearchUpgradeOutperform—
15 Dec 2025Goldman SachsMaintainsNeutral—
14 Oct 2025Truist SecuritiesInitiatesHold—
30 Sept 2025JP MorganMaintainsOverweight—
4 Sept 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

IMVT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

IMVT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Nov 2026, Immunovant, Inc. returned +36.7% against +11.2% for the S&P 500, dividends included.

IMVT vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26IMVTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IMVT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Immunovant, Inc. (IMVT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−12.0×

Cheaper than 95% of US stocks

Price / sales
—
Price / book
10.5×

Cheaper than 8% of US stocks

EV / EBITDA
−11.5×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 29% of US stocks

Returns & dividend
Return on equity
−86.5%

Higher than 15% of US stocks

Return on assets
−50.1%

Higher than 8% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Immunovant, Inc. (IMVT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Immunovant, Inc. has a market value of $6.9B and an enterprise value of $6.2B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$538.2M.

  • Diluted earnings per share, trailing twelve months: −$2.82.

  • Free cash flow in the twelve months to 30 June 2026: −$414.3M.

  • Shares outstanding: 206.3M.

  • Trailing P/E: −12.0×; forward P/E: −11.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Immunovant, Inc. employs 315 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

IMVT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IMVTImmunovant, Inc.$6.9B58
KODKodiak Sciences, Inc.$6.6B59
ORKAOruka Therapeutics, Inc.$6.6B37
TWSTTwist Bioscience Corp.$6.9B62
AXSMAxsome Therapeutics, Inc.$7.1B73
IBRXImmunityBio, Inc.$6.3B40
ARWRArrowhead Pharmaceuticals, Inc.$6.2B41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Immunovant, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IMVT news & analysis

Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?

Zacks Investment Research · 11 Nov 2026positive

Zacks reports that Wall Street analysts’ average price target for Immunovant implies 30.5% potential upside. It notes the metric’s effectiveness is questionable, while positive earnings estimate revisions may point to upside.

Why it matters — IMVT watchers may note the analyst-target estimate and the cited positive trend in earnings estimate revisions, alongside the stated caveat about the metric.

Immunovant (IMVT) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research · 11 Nov 2026positive

Immunovant was upgraded to Zacks Rank #2 (Buy), reflecting increased optimism about its earnings prospects. The source says this could support near-term stock movement.

Why it matters — The upgrade signals a more favorable view of Immunovant’s earnings prospects for investors following the company.

Immunovant, Inc. (IMVT) Q2 2027 Earnings Call Transcript

Seeking Alpha · 9 Nov 2026neutral

Seeking Alpha published a transcript of Immunovant, Inc.’s Q2 2027 earnings call, dated November 9, 2026. Listed company participants were Stephanie Lee Griffin and Matthew Gline of Roivant Sciences Ltd.

Why it matters — The transcript provides IMVT watchers with a record of the company’s Q2 2027 earnings-call discussion.

Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study

Benzinga · 9 Nov 2026positive

Immunovant announced positive efficacy results from a clinical trial evaluating IMVT-1402 in patients with difficult-to-treat rheumatoid arthritis. The headline says the study met its primary endpoint.

Why it matters — The trial result is relevant to IMVT watchers following development of IMVT-1402 for difficult-to-treat rheumatoid arthritis.

What Immunovant (IMVT) Said on Its Q2 Earnings Call

MarketBeat · 9 Nov 2026neutral

Roivant reported $31 million in net revenue from the initial launch of LISRAYA and highlighted new rheumatoid arthritis data for IMVT-1402 on its fiscal second-quarter earnings call. CEO Matt Gline noted the LISRAYA results covered about five weeks on the market and included a boost from pharmacy inventory.

Why it matters — IMVT watchers may note the highlighted IMVT-1402 rheumatoid arthritis data alongside the caution about interpreting early LISRAYA launch revenue.

FAQ

Frequently asked questions about IMVT stock

What is the IMVT stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Immunovant, Inc. have a median 12-month price target of $48, with estimates ranging from $33 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IMVT stock a buy right now?

Of the 17 analysts covering Immunovant, Inc., 13 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immunovant, Inc. 58 out of 100 across roughly 4,600 US stocks as at 16 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMVT?

As at 16 Nov 2026, Immunovant, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (85 of 100).

Will IMVT stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +44.5% from the last close, and Ticker Nerd's factor model ranks Immunovant, Inc. 58 out of 100 as at 16 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IMVT stock forecast for 2030?

No analyst covering Immunovant, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMVT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $33 to $62 over the next 12 months.

How has IMVT stock performed over the past year?

Immunovant, Inc. returned +36.7% over the 12 months to 17 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Immunovant, Inc. do?

Immunovant Inc. is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases.

What is the latest news on IMVT?

The most recent item we track (Zacks Investment Research, 11 Nov 2026): "Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?". Zacks reports that Wall Street analysts’ average price target for Immunovant implies 30.5% potential upside. It notes the metric’s effectiveness is questionable, while positive earnings estimate revisions may point to upside.

Company

About Immunovant, Inc.

Immunovant Inc. is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases. The company’s current work centers on antibody-based treatments that inhibit the neonatal Fc receptor, a mechanism designed to lower harmful IgG autoantibodies involved in multiple immune-mediated conditions. Its pipeline includes investigational programs such as IMVT-1402 and batoclimab, which are being studied across diseases including myasthenia gravis, thyroid eye disease, Graves’ disease, chronic inflammatory demyelinating polyneuropathy, rheumatoid arthritis, and related autoimmune disorders. Immunovant Inc. operates within the biopharmaceutical sector and is positioned as a specialist in FcRn-based immunology research, with an emphasis on advancing therapies that address the complex biology of autoimmune disease.

CEO Dr. Eric Venker M.D., Pharm.D. · 315 employees · United States · https://immunovant.com